By Finowings | June 2026
If you have been tracking the SME IPO space this week, the Genxai Analytics IPO GMP is one number that deserves your attention. The company has opened its subscription window and investors are actively watching the grey market premium to gauge listing day expectations. Here is everything you need to know before you decide to apply.
Genxai Analytics IPO is a book-build issue worth ₹54.84 crores, comprising entirely of a fresh issue of 0.47 crore shares. Since the issue is 100% fresh, the entire proceeds will flow directly into the company for its stated business objectives — no existing promoters are offloading shares through an Offer for Sale (OFS). For retail investors, a pure fresh issue is generally a positive signal as it indicates the company is raising capital for growth rather than an exit by early stakeholders.
Genxai Analytics IPO GMP — What the Grey Market Is Saying
The Genxai Analytics IPO GMP (Grey Market Premium) reflects the unofficial demand for the stock before it officially lists. GMP is an important indicator of market sentiment, though it is not an official metric and can fluctuate rapidly based on overall market conditions and subscription numbers. Investors should track the GMP alongside subscription data to make a more informed decision. At Finowings, we always recommend using GMP as just one data point — not the sole basis for your application decision.
IPO Key Dates
Here is a quick timeline to mark on your calendar:
Subscription Opens: June 5, 2026
Subscription Closes: June 9, 2026
Allotment Finalisation: June 10, 2026
Tentative Listing Date: June 12, 2026 (NSE SME)
The listing window is tight — just seven days from opening to trading. If you are planning to apply, ensure your UPI mandate is approved well before the closing date.
Price Band, Lot Size & Minimum Investment
The price band is set at ₹110 to ₹116 per share. Applications are made in lots of 1,200 shares each.
Note that the minimum investment for retail investors is ₹2,78,400 — this is on the higher side for an SME IPO, so investors should plan their funds accordingly before the subscription closes.
Should You Apply? Finowings' Take
The Genxai Analytics IPO presents an interesting opportunity in the SME segment. A few things stand out — a pure fresh issue structure, a well-defined price band, and a swift listing timeline that keeps capital locked up for a shorter period. That said, SME IPOs carry higher risk compared to mainboard issues, and liquidity post-listing on NSE SME can be limited.
At Finowings, our advice is straightforward: review the company's Draft Red Herring Prospectus (DRHP), understand the business fundamentals, track the live subscription status across all three categories, and only then factor in the GMP. A high GMP with poor fundamentals is not a recipe for long-term gains.
Final Word
The Genxai Analytics IPO GMP has been one of the buzzworthy terms among SME IPO watchers this week. With listing slated for June 12, 2026 on the NSE SME platform, the window to act is narrow. Stay updated with Finowings for live GMP updates, subscription status, and allotment results as they come in.
Disclaimer: This blog is for informational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before investing.
Post a Comment